Exploring depression in Parkinson's disease : an Italian Delphi Consensus on phenomenology, diagnosis, and management
© 2023. The Author(s)..
BACKGROUND: Depression is a prodromic and a frequent non-motor symptom of Parkinson's disease, associated to reduced quality of life and poor outcomes. The diagnosis of depression in parkinsonian patients represents a challenge due to the overlapping of symptoms typical of the two conditions.
METHODS: A Delphi panel survey was performed to reach a consensus amongst different Italian specialists on four main topics: the neuropathological correlates of depression, main clinical aspects, diagnosis, and management of depression in Parkinson's disease.
RESULTS AND CONCLUSION: Experts have recognized that depression is an established risk factor of PD and that its anatomic substrate is related to the neuropathological abnormalities typical of the disease. Multimodal and SSRI antidepressant have been confirmed as a valid therapeutic option in the treatment of depression in PD. Tolerability, safety profile, and potential efficacy on broad spectrum of symptoms of depression including cognitive symptoms and anhedonia should be considered when selecting an antidepressant and the choice should be tailored on the patients' characteristics.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
---|---|
Enthalten in: |
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology - 44(2023), 9 vom: 26. Sept., Seite 3123-3131 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Stocchi, Fabrizio [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antidepressive Agents |
---|
Anmerkungen: |
Date Completed 11.08.2023 Date Revised 14.08.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s10072-023-06740-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM356045447 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM356045447 | ||
003 | DE-627 | ||
005 | 20231226065627.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10072-023-06740-w |2 doi | |
028 | 5 | 2 | |a pubmed24n1186.xml |
035 | |a (DE-627)NLM356045447 | ||
035 | |a (NLM)37100925 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Stocchi, Fabrizio |e verfasserin |4 aut | |
245 | 1 | 0 | |a Exploring depression in Parkinson's disease |b an Italian Delphi Consensus on phenomenology, diagnosis, and management |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.08.2023 | ||
500 | |a Date Revised 14.08.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a BACKGROUND: Depression is a prodromic and a frequent non-motor symptom of Parkinson's disease, associated to reduced quality of life and poor outcomes. The diagnosis of depression in parkinsonian patients represents a challenge due to the overlapping of symptoms typical of the two conditions | ||
520 | |a METHODS: A Delphi panel survey was performed to reach a consensus amongst different Italian specialists on four main topics: the neuropathological correlates of depression, main clinical aspects, diagnosis, and management of depression in Parkinson's disease | ||
520 | |a RESULTS AND CONCLUSION: Experts have recognized that depression is an established risk factor of PD and that its anatomic substrate is related to the neuropathological abnormalities typical of the disease. Multimodal and SSRI antidepressant have been confirmed as a valid therapeutic option in the treatment of depression in PD. Tolerability, safety profile, and potential efficacy on broad spectrum of symptoms of depression including cognitive symptoms and anhedonia should be considered when selecting an antidepressant and the choice should be tailored on the patients' characteristics | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Delphi Consensus | |
650 | 4 | |a Depression | |
650 | 4 | |a Multimodal antidepressants | |
650 | 4 | |a Parkinson’s disease | |
650 | 4 | |a SSRI | |
650 | 7 | |a Antidepressive Agents |2 NLM | |
700 | 1 | |a Angelo Antonini |e verfasserin |4 aut | |
700 | 1 | |a Barone, Paolo |e verfasserin |4 aut | |
700 | 1 | |a Bellelli, Giuseppe |e verfasserin |4 aut | |
700 | 1 | |a Fagiolini, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Ferini Strambi, Luigi |e verfasserin |4 aut | |
700 | 1 | |a Sorbi, Sandro |e verfasserin |4 aut | |
700 | 1 | |a Padovani, Alessandro |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology |d 2000 |g 44(2023), 9 vom: 26. Sept., Seite 3123-3131 |w (DE-627)NLM108608468 |x 1590-3478 |7 nnns |
773 | 1 | 8 | |g volume:44 |g year:2023 |g number:9 |g day:26 |g month:09 |g pages:3123-3131 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10072-023-06740-w |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 44 |j 2023 |e 9 |b 26 |c 09 |h 3123-3131 |